COMMON STOCK PURCHASE WARRANT To Purchase Shares of Common Stock of Pro- Pharmaceuticals, Inc.Common Stock Purchase Warrant • April 9th, 2004 • Pro Pharmaceuticals Inc • Pharmaceutical preparations
Contract Type FiledApril 9th, 2004 Company IndustryTHIS COMMON STOCK PURCHASE WARRANT CERTIFIES that, for value received, (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after April 8, 2004 (the “Initial Exercise Date”) and on or prior to the close of business on April 7, 2009 [in the case of Rodman & Renshaw, Inc., April 7, 2007] (the “Termination Date” and the period from the Initial Exercise Date until the Termination Date, the “Exercise Period”)) but not thereafter, to subscribe for and purchase from Pro-Pharmaceuticals, Inc., a corporation incorporated in the State of Nevada (the “Company”), up to shares (the “Warrant Shares”) of Common Stock, of the Company (the “Common Stock”). The purchase price of one share of Common Stock (the “Exercise Price”) under this Warrant shall be $5.30, subject to adjustment hereunder. The Exercise Price and the number of Warrant Shares for which the Warrant is exercisable shall be subject to adjustment
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 9th, 2004 • Pro Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledApril 9th, 2004 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of April 7, 2004, among Pro-Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and the purchasers identified on the signature pages hereto (each a “Purchaser” and collectively the “Purchasers”); and
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 9th, 2004 • Pro Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledApril 9th, 2004 Company Industry JurisdictionThis Registration Rights Agreement (this “Agreement”) is made and entered into as of April 7, 2004, by and among Pro-Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and the investors signatory hereto (each a “Purchaser” and collectively, the “Purchasers”).